Generic versions of capmatinib and differences in origin

Capmatinib is a highly selective MET tyrosine kinase inhibitor, mainly used to treat patients with MET exon 14 skipping mutation-positive non-small cell lung cancer (NSCLC). The drug was developed by Novartis, with the original trade name Tabrecta, and has been approved for marketing in Europe, the United States and other countries. Due to its broad clinical application prospects and precise targeting, capmatinib has quickly attracted the attention of many generic drug manufacturers around the world, especially in Southeast Asian countries with relatively open generic drug policies.

Currently, multiple generic versions of capmatinib have appeared in overseas markets, especially in Laos. These drugs are basically consistent with the original drug in terms of chemical composition, dosage form, specifications and efficacy, and are equivalent generic drugs. Common generic drug manufacturers include Lao United Pharmaceuticals, Lao Lucius Pharmaceuticals, Lao Elements Pharmaceuticals and Lao Second Pharmaceuticals, etc. These companies have local certification qualifications.

The generic version of capmatinib is usually 200 mg × 56 tablets/box, and is designed to be consistent with the original drug, making it easier to maintain the recommended twice-daily dosing regimen. The price is significantly lower than that of the original drug. If the original drug is not included in the medical insurance, the monthly treatment cost can be as high as tens of thousands of yuan, while the price of a box of Laos generic drugs is about RMB 2,000. Although it may change due to exchange rate fluctuations or channel differences, the overall price significantly reduces the financial burden of patients. This price advantage has led many self-pay patients to choose to obtain Laos generic drugs through third-party cross-border medical platforms and other methods.

In summary, the generic drug of capmatinib is highly consistent with the original drug in terms of efficacy and ingredients, and is one of the important choices for price-sensitive patients. Many pharmaceutical companies in Laos are actively seizing this targeted therapy market, promoting the circulation of capmatinib generic drugs in Southeast Asia and some cross-border markets, providing a realistic and feasible alternative to the original drug.

Reference materials:https://www.drugs.com/mtm/capmatinib.html